Study on Dalfampridine in the treatment of Multiple Sclerosis Mobility Disability: A meta-analysis

Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine

(2018) Jeremy Hobart et al.   CNS DRUGS

Dalfampridine benefits ambulation but not cognition in multiple sclerosis

(2018) Nikhil Satchidanand et al.   Multiple Sclerosis Journal

Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis

(2017) Robert W Motl et al.   Multiple Sclerosis Journal

Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis

(2017) Robert W Motl et al.   Multiple Sclerosis Journal

4-Аminopyridine sequesters intracellular Ca2+ which triggers exocytosis in excitable and non-excitable cells

(2016) Ludmila A. Kasatkina   Scientific Reports

Effect of slow release-Fampridine on muscle strength, rate of force development, functional capacity and cognitive function in an enriched population of MS patients. A randomized, double blind, placebo controlled study

(2016) H.B. Jensen et al.   Multiple Sclerosis and Related Disorders

Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial

(2015) Raymond Hupperts et al.   Multiple Sclerosis Journal

Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial

(2015) Raymond Hupperts et al.   Multiple Sclerosis Journal

Pharmacology and clinical efficacy of dalfampridine for treating multiple sclerosis

(2014) Alessandra Lugaresi   Expert Opinion on Drug Metabolism & Toxicology

Consensus guidelines for the diagnosis and treatment of multiple sclerosis

(2013) B. Yamout et al.   CURRENT MEDICAL RESEARCH AND OPINION

Disability in multiple sclerosis: A reference for patients and clinicians

(2013) I. Kister et al.   NEUROLOGY

4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review

(2013) Henrik Boye Jensen et al.   Therapeutic Advances in Neurological Disorders

Teriflunomide in relapsing multiple sclerosis: therapeutic utility

(2013) Mark S. Freedman   Therapeutic Advances in Chronic Disease

The Safety Profile of Dalfampridine Extended Release in Multiple Sclerosis Clinical Trials

(2012) David R. Cornblath et al.   CLINICAL THERAPEUTICS

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

(2011) Chris H. Polman et al.   ANNALS OF NEUROLOGY

Exercise in multiple sclerosis -- an integral component of disease management

(2011) Andrea Döring et al.   EPMA Journal

A phase 3 trial of extended release oral dalfampridine in multiple sclerosis

(2010) Andrew D. Goodman et al.   ANNALS OF NEUROLOGY

Impact of mobility impairment on the burden of caregiving in individuals with multiple sclerosis

(2010) Jeffrey Dunn   Expert Review of Pharmacoeconomics & Outcomes Research

Pharmacokinetics of 14C-radioactivity after oral intake of a single dose of 14C-labeled fampridine (4-aminopyridine) in healthy volunteers

(2009) Andrew R. Blight et al.   CLINICAL THERAPEUTICS

Aminopyridines Potentiate Synaptic and Neuromuscular Transmission by Targeting the Voltage-activated Calcium Channel β Subunit

(2009) Zi-Zhen Wu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial

(2009) Andrew D Goodman et al.   LANCET

Multiple sclerosis

(2008) Alastair Compston et al.   LANCET